Santhera has an exclusive license for all indications worldwide to AGAMREE® (vamorolone), a first-in-class dissociative steroid with a novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy as an alternative to standard corticosteroids. AGAMREE is approved for the treatment of DMD in the U.S., the EU and the UK.